Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ozone therapy put to the test: could it harm your eyes?

NCT ID NCT07718100

Knowledge-focused Sponsor: Yuzuncu Yil University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study investigates whether systemic ozone therapy, used for conditions like chronic pain and osteoarthritis, damages the corneal endothelium—the eye's inner layer that keeps the cornea clear. Researchers will compare 48 patients receiving ozone therapy with 48 healthy matched controls, measuring corneal cell health and oxidative stress markers over six months. The goal is to determine if this increasingly popular treatment is safe for the eyes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
systemic ozone therapy (major autohemotherapy)
What this could lead to
If safe, it may support wider use of ozone therapy for pain and inflammation without worrying about eye damage.
What could go wrong
This is a small, early safety study, not a test of effectiveness. It may find no harm, but results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

96 people

The number who actually took part.

Started

Jan 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * For ozone group: Patients scheduled to receive systemic ozone therapy for fibromyalgia, chronic pain, knee osteoarthritis, disk herniation, peripheral arterial disease, or sports injuries * For control group: Healthy individuals matched for age (±2 years), sex, and body mass index (BMI, ±3 kg/m²) * Willing and able to provide written informed consent * Willing and able to comply with all study procedures and follow-up visits Exclusion Criteria: * History of ocular surgery or trauma * Corneal dystrophy or degeneration * Glaucoma or ocular hypertension * Diabetes mellitus * Contact lens use within the preceding 3 months * Active ocular surface disease * Systemic conditions known to affect corneal endothelium * Any condition that, in the opinion of the investigator, would interfere with study participation or evaluation of outcomes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pain are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic pain syndrome Corneal Endothelial Cell Loss fibromyalgia osteoarthritis, knee peripheral arterial disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Corneal endothelial cell loss Ozone therapy

Contacts and locations

Locations

  • Yuzuncu Yil University

    Van, 65080, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.